



Autoanticorpi anti-MZGP2

Acronimo MZGP2 (Major zymogen granule glycoprotein 2)

Prevalenza Morbus Crohn

Metodi della ricerca ELISA

Bibliografia

Bogdanos DP, Rigopoulou EI, Smyk DS, Roggenbuck D, Reinhold D, Forbes A, Laass MW, Conrad K. Diagnostic value, clinical utility and pathogenic significance of reactivity to the molecular targets of Crohn's disease specific-pancreatic autoantibodies. *Autoimmun Rev* (2011) ; 11(2): 143 - 148 (PMID: [21983481](#)).

Pavlidis P, Romanidou O, Roggenbuck D, Mytilinaiou MG, Al-Sulttan F, Liaskos C, Smyk DS, Koutsoumpas AL, Rigopoulou EI, Conrad K, Forbes A, Bogdanos DP: Ileal inflammation may trigger the development of GP2-specific pancreatic autoantibodies in patients with Crohn's disease. *Clin Dev Immunol* (2012); 2012: 640835 (PMID: [23118780](#)).

Roggenbuck D, Hausdorf G, Martinez-Gamboa L, Reinhold D, Büttner T, Jungblut PR, Porstmann T, Laass MW, Henker J, Büning C, Feist E, Conrad K: Identification of GP2, the major zymogen granule membrane glycoprotein, as the autoantigen of pancreatic antibodies in Crohn's disease. *Gut* (2009); 58(12): 1.620 - 1.628 (PMID: [19549613](#)).

Roggenbuck D, Reinhold D, Wex T, Goehl A, von Arnim U, Malfertheiner P, Büttner T, Porstmann T, Porstmann S, Liedvogel B, Bogdanos DP, Laass MW, Conrad K: Autoantibodies to GP2, the major zymogen granule membrane glycoprotein, are new markers in Crohn's disease. *Clin Chim Acta* (2011); 412(9-10): 718 - 724 (PMID: [21195704](#)).

Roggenbuck D, Reinhold D, Werner L, Schierack P, Bogdanos DP, Conrad K: Glycoprotein 2 antibodies in Crohn's disease. *Adv Clin Chem* (2013); 60:187 - 208 (PMID: [23724745](#)).